VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn’s disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand

  title={VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn’s disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand},
  author={Richard B. Gearry and Chris Frampton and Stephen J. Inns and David Poppelwell and Marius Rademaker and Ravi Suppiah},
  journal={Current Medical Research and Opinion},
  pages={1837 - 1846}
Abstract Objective: VITALITY, a 6-month, multicenter, prospective, observational study, assessed the effects of originator adalimumab (HUMIRA) on health and disability outcomes in patients with Crohn’s disease (CD), rheumatoid arthritis (RA), or psoriasis treated in routine clinical practice in New Zealand (NZ). Methods: Biologic-naïve adults initiating adalimumab in accordance with NZ funding requirements were recruited. The primary endpoint was 6-month change from baseline in World Health… Expand
4 Citations
Why does Pharmac neglect inflammatory bowel disease?
Crohn’s disease and ulcerative colitis are chronic, incurable, inflammatory diseases that follow a relapsing and remitting course and in times of flare can lead to hospitalisation, often coupled with abdominal and perianal surgery, followed by varying periods of recovery. Expand
Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors
The results illustrate that single-chain soluble receptor fusion proteins against IL-4, IL-13, and IL-33 are novel biologics that might not only be of interest for research purposes and further interrogation of the role of their target cytokines in physiology and disease, but may also complement monoclonal antibodies for the treatment of allergic and other inflammatory diseases. Expand
  • Reactions Weekly
  • 2019


Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial
Adalimumab maintenance therapy provided sustained improvements in HRQOL for patients with moderate to severe Crohn's disease through week 56, compared with patients who were assigned to placebo after induction therapy. Expand
Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study
Adalimumab plus MTX significantly improved physical functioning and HRQOL in patients with early RA over 2 years of treatment, and both SF-6D and HUI-3 were found to be sensitive preference-based measures for assessing the effects of treatment on multidimensional function. Expand
Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis
A 1-year delay in receipt of adalimumab + MTX was associated with reduced effectiveness, suggesting that a window of opportunity to prevent irreversible damage exists even in a population with established RA. Expand
Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab.
In regular practice, adalimumab is clinically effective in the treatment of Crohn's disease patients and results in a significant improvement in quality of life and work productivity. Expand
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
Adalimumab therapy significantly improved work productivity and disease-specific quality of life for patients with moderate to severe Crohn's disease, with potentially greater benefits for infliximab-naïve patients. Expand
Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study
Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA and the rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. Expand
The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial.
The proposed short version of the inflammatory bowel disease questionnaire, the SIBDQ, is valid, reliable, and able to detect meaningful clinical changes in HRQOL that might occur in the office setting. Expand
Disability in Patients with Inflammatory Bowel Disease: Correlations with Quality of Life and Patient's Characteristics
CD patients were facing more limitations compared to those with UC, especially in the domains of relationships, activities, and participation, and sociodemographic characteristics were also associated with increased disability. Expand
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
Among early RA patients with elevated risk of employment loss, ADA +MTX therapy was associated with a significant reduction in work instability vs PBO + MTX. Expand
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
In this 52-week trial, adalimumab was more effective than placebo at inhibiting the progression of structural joint damage, reducing the signs and symptoms, and improving physical function in patients with active RA who had demonstrated an incomplete response to MTX. Expand